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DELAYED IMMUNE RECOVERY AFTER UMBILICAL CORD BLOOD
TRANSPLANTATION (UCBT) IS CHARACTERIZED BY THYMIC REGEN-
ERATION FAILURE
Krishna V. Komanduri, Lisa S. St. John, Susan Bryan, Sean Martin,
John D. McMannis, Jeffrey J. Molldrem, Richard E. Champlin, Lau-
rence J. Cooper, Laura Worth, Demetrios Petropoulos, Chitra Hosing,
Daniel M. Couriel, Marcos de Lima, Elizabeth J. Shpall Dept. of Blood
and Marrow Transplantation, Univ. of Texas M.D. Anderson Cancer
Center, Houston, TX
UCBT is a potentially curative modality for many patients with
relapsed or high-risk hematological malignancies who lack suitably
matched hematopoietic progenitor cell donors. The advent of
transplant approaches that combine multiple CB units to facilitate
transplantation into adult recipients, as well as advances in condi-
tioning regimens and supportive care, have signiﬁcantly improved
outcomes following UCBT. Despite these advances, infections
and/or relapse associated with impaired T cell reconstitution re-
mains an important source of morbidity and mortality. We pro-
spectively assessed the quantitative and functional recovery of
CD4 and CD8 T cells in 34 consecutively transplanted adult
UCBT recipients. Functional studies of CD4 and CD8 T cells
stimulated with a superantigen (staphylococcal enterotoxin B,
SEB) and cytomegalovirus (CMV) antigens revealed that SEB-
stimulated IFN responses by cytokine ﬂow cytometry (CFC) were
signiﬁcantly lower in the UCBT recipients than in control bone
marrow or peripheral blood stem cell transplant (SCT) recipients
(median values of 0.99% (n12) vs. 24.8% (n24) in the CD4
compartment and 0.62% (n14) vs. 6.37% (n9) in the CD8
compartment, respectively). Despite this, many UCBT recipients
had measurable donor-derived CMV-speciﬁc CD4 and CD8 T
cells by 3 months (4 of 11, 44% in CD4 T cells and 6 of 12, 50%
amongst CD8 T cells), indicating that primary immune responses
were derived from the naı¨ve CB graft precursors. Immunophenotypic
studies demonstrated that a higher proportion of effector and late-
effector memory cells (i.e., CCR7-CD45RA- and CCR7-CD45RA
T cells) were present in UCBT recipients than SCT recipients. The
median fraction of CCR7-negative T cells was 65% (n12, UCBT
recipients) vs. 30% (n21, other SCT recipients) in the CD4 com-
partment, and 76% vs. 31%, respectively, in the CD8 compartment.
Furthermore, the subgroup of UCBT recipients with a ratio of
CCR7 to CCR7-negative CD4T cells above themedian at day 30
after SCT survived signiﬁcantly longer (666 days vs. 224 days,
p0.03). Finally, we compared thymic regeneration (using a -chain
T cell receptor excision, TREC assay) in UCBT recipients with
three other groups of SCT recipients, including longitudinally as-
sessed autologous and allogeneic SCT recipients, as well another
group of allogeneic SCT recipients assessed cross-sectionally. Thymic
recovery was reduced at one and three months after UCBT, relative
to all other SCT recipient groups.Median TREC values (reported as
TRECs/million PBMC) at three months were 0.0 in UCBT recip-
ients (n12), 12 in autologous SCT recipients (n11), 124 in allo-
geneic SCT recipients (n27), and 2150 in a second group of allo-
geneic SCT recipients (n31) (p0.04 for all observations). These
results demonstrate that T cell immune recovery in UCBT recipients
is characterized by delayed functional rcovery and a relative predom-
inance of late memory (CCR7-) T cells, relative to other SCT recip-
ients. However, naı¨ve donor-derived CB cells are capable of primary
pathogen-speciﬁc expansion in vivo. Finally, these data suggest that
efforts to improve T cell immune reconstitution after UCBT should
be directed at improving thymic regeneration, which is likely to be
important in facilitating the recovery of naı¨ve and early memory T
cells.
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CYTOTOXIC T LYMPHOCYTE THERAPY FOR THE TREATMENT AND
PREVENTION OF ADENOVIRUS INFECTION AFTER TRANSPLANT
Catherine M. Bollard, MD Baylor College of Medicine, Houston, TX
Adenoviruses (Adv) remain a major cause of mortality and mor-
bidity in hematopoietic stem cell transplant (SCT) and cord blood
transplant (CBT) recipients. We evaluated the use of Adv-speciﬁc
cytotoxic T lymphocytes (CTL) for prophylaxis and treatment of
Adv infections post SCT. CTLs were initiated by infecting donor-
derived mononuclear cells with the either the Ad5f35pp65 or the
Ad5f35 vector. Responder cells were expanded by weekly restimu-
lation with autologous EBV-transformed B lymphoblastoid cell
lines (LCL) transduced with either Ad5f35 or Ad5f35pp65. 13 of
29 CTL lines manufactured for clinical use were predominantly
CD4 (range 12-99%), but all had a CD8 component (range
3.5-95%). 27/29 CTL lines showed speciﬁc killing of Adv beariung
targets and all lines showed killing of EBV antigen-bearing target
cells. All CTL lines generated using antigen presenting cells in-
fected with the Ad5f35pp65 vector showing killing of CMVpp65
targets which was the dominant response. Recognition of Adv and
EBV targets was not signiﬁcantly different; at 20:1 effector:target
ratio there was 16.8
13% speciﬁc lysis of Adv targets and
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17.5% lysis of EBV targets while uninfected recipient target
cells were not lysed (2
2.7%). Hexon was the immunodominant
Adv antigen in all CTL lines with Adv-speciﬁc activity. To test the
hypothesis that polyclonal hexon-speciﬁc T cells can provide pro-
tection against Adv infections in SCT recipients, we administered
donor-derived bi or tri-virus-speciﬁc CTL lines to recipients after
allogeneic SCT. We have treated 20 patients in this phase I dose
escalation study. Patients received doses ranging from 5x106/m2 to
1.35108/m2. Of 15 patients who received CTL as prophylaxis, all
remain negative for Adv, EBV and CMV. No adverse events
attributable were to CTL infusion. Increased EBV-speciﬁc T cell
frequency was detected in the peripheral blood (PB) 2wks post
infusion in all patients, likely due to the presence of this latent virus
in all. Increased CMV-speciﬁc T cell frequency was detected in the
peripheral blood (PB) 2wks post infusion in all patients who re-
ceived tri-virus speciﬁc CTL. However, there was no signiﬁcant
rise in Adv-speciﬁc T cell frequency post-infusion except in the 5
patients who had recent or active infection. All patients cleared
their Adv infection. This included one patient who received CTL
(5x106/m2) as treatment for Adv disease. This patient had Adv
pneumonia requiring ventilatory support. Post-CTL the patient
made a dramatic clinical recovery, was weaned off mechanical
ventilation, and discharged a month after infusion. In contrast to
the prophylaxis group, this patient had a substantial rise in Adv-
speciﬁc T cells in PB by 4wks post CTL, which coincided with
clinical recovery and clearance of Adv from the tracheal aspirate,
suggesting that the infused cells were effective in vivo. Adoptive
immunotherapy for Adv appears safe but expansion of Adv-speciﬁc
CTL in vivo may require the presence of antigen to stimulate the
infused cells. Strategies to translate this approach to the cord blood
setting will be discussed.
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STRATEGY TO COMBAT OPPORTUNISTIC INFECTIONS AFTER UMBILI-
CAL CORD BLOOD TRANSPLANTATION (UCBT) - MONITORING OF
MULTIPLE PATHOGENS WITH A NOVEL MULTIPLEX PCR SYSTEM AND
INFUSION OF EX-VIVO EXPANDED CD4 T-CELLS (CD4-DLI)
Tomohiro Morio, MD, PhD Department of Pediatrics and Developmen-
tal Biology Tokyo Medical and Dental University Graduate School of
Medicine Centre for Cell Therapy, Tokyo Medical and Dental University
Medical Hospital
Infectious complications are a major cause of morbidity and
mortality in patients undergoing hematopoietic stem cell trans-
plantation. Although the risk of serious infection after pediatric
umbilical cord blood transplantation (UCBT) is reported to be
comparable to that with unmanipulated BM, several line of evi-
dence now shows high incidence of EBV-related complications,
VZV reactivation, HHV6 infection, and CMV infection in CBT-
recipients. A system for sensitive and rapid monitoring of multiple
viruses is fundamental to pinpoint target pathogen(s) and to start
anti-microbial therapy in a timely manner. We have developed a
novel system that employs a melting curve analysis on multiplex
PCR products, a system that is designed to detect 17 viruses:
HSV1, HSV2, VZV, EBV, CMV, HHV6, HHV7, HHV8, BK
virus, JC virus, Parvovirus B19, HBV, HIV1, HIV2, HTLV1,
HTLV2, and HCV. The lowest detectable level is less than 20
1400
copies/ sample, and the whole procedure from DNA extraction to
analysis requires less than 2 hours. The positive sample can be
further quantitated by using real time PCR. We also developed real
time PCR system to measure copy number of HAV, HEV, GBV,
Adenovirus, Norovirus, Metapneumovirus, Pn. jirovecci, Toxo-
plasma, and Cryptosporidium. Analysis of 980 samples from 145
patients who underwent SCT revealed that 18% of blood/urine
samples were positive for more than one virus. Although infections
with multiple viruses were less frequent in CBT-recipient than
allogeneic BMT/PBSCT-recipients, most of the CBT-recipients
with coinfection/superinfection showed profound immunodeﬁ-
ciency. Serious virus infection such as ganciclovir-resistant CMV
infection was noted in 9 out of 40 CBT-recipients. Opportunistic
infections in CBT stem from secondary immunodeﬁciency, which
often leads to predisposition to other infections, and to indirect
consequences such as graft rejection and leukemic relapse. Mea-
sures to facilitate rapid immune reconstitution would result in
control of ongoing infection and reduce non-relapse mortality.
Donor lymphocyte infusion (DLI), although not available in CBT-
recipients, would potentially be effective for opportunistic infec-
tions. We have developed a simple method for expanding activated
donor CD4-T cells from cord blood mononuclear cells (MNCs).
CD4 T-cell function such as cytokine production, was comparable
to those of adult expanded CD4 T-cells. Infusion of CD4 T-cells
expanded from cord blood was effective for viral infections such as
drug-resistant CMV disease and Coxsackie B hemorrhagic colitis.
Aggravation of GVHD, cytopenia, or organ damage was not noted
in CD4-DLI for these patients. Preparation of expanded CD4
T-cells from engrafted MNCs with low CD4 T-cells is sometimes
challenging. We would need to decide whether CD4 T-cells
should be expanded for high risk patients or for all the recipients in
advance. CD4-DLI would serve as “the second generation DLI” in
CBT since it needs small amount of blood; stimulates various limbs
of immune system; and is associated with minimal side effects.
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STEM CELLS IN THE UMBILICAL CORD MATRIX: ISOLATION AND CHAR-
ACTERIZATION
Mark L. Weiss Kansas State University, Dept of Anatomy and Physi-
ology, Midwest Institute for Comparative Stem Cell Biology, Manhattan,
KS 66506, USA
The umbilical cord is a non-controversial source of mesenchy-
mal-like stem cells (MSCs). Work from several laboratories shows
that MSCs can be isolated from several different compartments of
the umbilical cord including the umbilical cord blood (UCB), the
amnion and amniotic ﬂuid, the perivascular compartment, etc.
Work with cells derived from Wharton’s Jelly that have been
termed umbilical cord matrix (UCM) cells will be described here.
UCM cells are plastic-adherent cells that have similar surface
phenotype, differentiation potential and physiological properties to
MSCs derived from other tissues sources such as bone marrow and
adipose tissue. Unlike MSCs derived from “adult” sources, UCM
cells have several advantages, not the least of which is that they are
collected from a fairly homogenous, young population, minimal
surgical risk to patient, etc. Several labs have demonstrated a
therapeutic potential for the UCM cells in experimental disease
models, indicating the possibly that UCM cells may substitute cell
for bone marrow derived MSCs for cellular therapy, tissue engi-
neering, and biotechnology applications. Our lab and others have
demonstrated that UCM cells have a therapeutic effect in a rodent
model of Parkinson’s disease. Work in other laboratories indicates
that UCM cells may have a rescue function in other degenerative
disease. We envision that both umbilical cord blood and mesen-
chymal cells will be commercially collected and stored in the future
for experimental research and pre-clinical work, for public and
private banking services, etc. While Standard Operating Proce-
dures (SOPs) exist for UCB banking, SOPs are yet to be developed
for clinical-grade UCM cells. Some of hurdles that have been
identiﬁed for the generation of clinical-grade UCM cells will be
discussed.
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MORPHOLOGICAL AND MOLECULAR CHARACTERIZATION OF NOVEL
POPULATION OF CXCR4 SSEA-4 OCT-4 VERY SMALL EMBRYONIC-
LIKE (VSEL) CELLS PURFIED FROM HUMAN CORD BLOOD
Mariusz Z. Ratajczak, Magda Kucia, Maciej Halasa, Marcin Wysoc-
zynski, Bogdan Machalinski Stem Cell Biology Program, James Graham
Brown Cancer Center, University of Louisville, Louisville, KY, USA and
Department of Physiopathology, Pomeranian Medical University, Szc-
zecin, Poland
Mononuclear cells (MNC) isolated from bone marrow (BM) or
cord blood (CB) contributes to organ/tissue regeneration, how-
ever, the identity of the speciﬁc cell type(s) involved remains
unknown. Recently we identiﬁed in murine BM a homogenous
population of rare (0.01% of BMMNC) Sca-1 CXCR4 lin
CD45 cells that express by RQ-PCR and immuno-histochemistry
markers of pluripotent stem cells (PSC) such as SSEA-1, Oct-4,
Nanog and Rex-1, highly express Rif-1 telomerase protein and
display several features typical for primary embryonic stem cells
such as i) a large nuclei surrounded by a narrow rim of cytoplasm,
and iii) open-type chromatin (euchromatin) that is typical for
embryonic stem cells (Leukemia 2006;20,857-869). These cells
(2-4 	m in diameter) were named very small embryonic-like
(VSEL) stem cells. We will present a new two step isolation
procedure to purify a similar population of cells from human CB,
which is based on isolation of CB mononuclear cells (CB MNC) by
hypotonic lysis and multiparameter FACS sorting. Accordingly, we
perform i) hypotonic lysis of CB to remove erythrocytes and to
enrich for CB MNC combined with ii) multiparameter sorting for
CXCR4AC133CD34linCD45 CB MNC. CB-derived
VSEL (CB-VSEL) isolated this way similarly as those isolated
from adult BM are very small (3-5 	m), possess large nuclei
containing unorganized euchromatin, express nuclear embryonic
transcription factors Oct-4 and Nanog and surface embryonic
antigen SSEA-4. VSEL do not express MHC class I and class II
antigens and are CD29, CD90 and CD105 negative. In vitro
cultures CB-VSEL are able to grow neurospheres that gave rise to
neuronal lineages (beta-III tubulin, nestin, O4, MBP,
GFAP) and cardiomyocytes (beta-myosin heavy chain, alpha-
sarcomeric actin. Based on this we conclude that CB contains
VSEL and that the majority of these CB VSEL are lost during
routine procedures employed currently for banking of CB MNC.
Thus based on our observations, new more efﬁcient methods of
CB banking are needed that will enrich/preserve these cells in CB
units during preparation before storage. Furthermore, we conclude
that CB tissue/organ regenerating potential may be much higher
than initially postulated if the proper fraction of CB MNC cells
enriched in VSEL is employed and we are currently testing this
hypothesis in animal models.
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GROWTH OF HIGH PROLIFERATIVE POTENTIAL ENDOTHELIAL COL-
ONY FORMING CELLS FROM UMBILICAL CORD BLOOD
Mervin C. Yoder and David A. Ingram Indiana University School of
Medicine, Indianapolis, IN
Adult peripheral blood has long been known to contain circulat-
ing endothelial cells. Since 1997, umbilical cord blood has been
known to contain a population of circulating cells that serve as
progenitors for the endothelial lineage (EPCs). We have deter-
mined that a rare population of cells in the umbilical cord blood
emerges upon in vitro culture that displays clonal colony forming
ability. These endothelial colony forming cells (ECFCs) are
present in adult peripheral blood as well, though vastly enriched in
term and preterm cord blood. ECFC display a hierarchy of pro-
liferative potential. Cells with the highest proliferative potential
(HPP) can replate into secondary and tertiary high proliferative
potential ECFC, but also give rise to low proliferative potential (do
not self-renew), endothelial clusters, and non-dividing mature en-
dothelial cells. HPP-ECFC display signiﬁcantly greater telomerase
activity than cells with lower proliferative potential. Cord blood
ECFC are capable of forming human vessels when implanted into
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